BIM
SYRE icon

BlackRock Investment Management’s Spyre Therapeutics SYRE Stock Holding History

BlackRock Investment Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$4K Hold
33
– – ﹤0.01% 3804
2016
Q3 		$5K Hold
33
– – ﹤0.01% 3783
2016
Q2 		$4K Buy
+33
New +$6.33K ﹤0.01% 3897

Other funds holding SYRE

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock Investment Management's SYRE Position: Q4 2016 in Review

BlackRock Investment Management held its Spyre Therapeutics (SYRE) position steady in Q4 2016 at 33 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #3804.

BlackRock Investment Management first reported a position in SYRE in Q2 2016 and has held it in 3 quarters since. The position peaked at $5K in Q3 2016. 26 funds tracked by Wall St. Rank hold SYRE as of Q4 2016.

  • BlackRock Investment Management held 33 shares of Spyre Therapeutics worth $4K as of Q4 2016.
  • BlackRock Investment Management left its Spyre Therapeutics share count unchanged in Q4 2016.
  • Spyre Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3804 holding.
  • BlackRock Investment Management first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • BlackRock Investment Management's Spyre Therapeutics position peaked at $5K in Q3 2016.
  • 26 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.